Risk factor modification remains as the principal aspect of care for stroke prevention. Understanding of risk factors has advanced and several options are now available to treat modifiable risk factors. However, effective treatment remains a challenging task in clinical practice. Prevention begins with awareness of risk factors by patients and clinicians. Risk factor assessment along with overall stroke risk estimation should be part of evaluation of patients with stroke, and used with careful clinical judgment. In this review, we discuss the impact of modifiable traditional vascular risk factors on ischemic stroke, interventions for stroke prevention, and evidence for early treatment of risk factors where available, as well as areas of research progress. Emphasis should be put on the education of patients, the community, and medical personnel. Future research in the field of genetic determinants of vascular risk factors and stroke will increase our understanding of the underlying mechanisms of cerebrovascular disease and likely result in development of new therapies and individualized programs for stroke prevention.
Introduction
The most effective means available for reducing the burden of stroke involve modification and treatment of vascular risk factors. Nevertheless, despite several available therapies for many of these risk factors, this task remains a challenge for clinicians and patients. Stroke remains as the leading cause of disability and the third cause of death in the United States. Approximately 780,000 new and recurrent strokes occur annually in the US. [Williams, 2001] The economic burden is tremendous, since many patients require chronic care [Thom et al. 2006 ] and long-term institutionalization, with an estimated cost of about 6.1 billion dollars for informal caregiving and total annual cost of US$ 30 billion in the US [Hickenbottom et al. 2002; Dobkin, 1995] .
Stroke prevention begins with recognition of its risk factors by a patient and clinicians treating the patient. However, patient awareness remains a limitation in the treatment of risk factors and most patients having a stroke have multiple risk factors. [Kannel, 2000] In addition, effective incorporation of evidence into practice, patient education, and patient encouragement to apply evidence in their lives by physicians, is also limited [Bodenheimer, 2007] .
past several years as a result of prospective epidemiological studies and several controlled clinical trials demonstrating effective therapies. These strategies target individual risk factors for the most part, but comprehensive treatment should involve overall risk assessment. For this purpose, models such as the Framingham Stroke Risk Profile (FSRP) have been developed, which are easy to use in clinical practice, providing an illustration for patient education regarding the impact of risk factors in stroke risk, and the effect of therapeutic interventions reducing this risk.
Effective modification of risk factors is a process involving patient education and a team approach, to reinforce patient understanding, follow up and confirm compliance with therapeutic measures, including medications.
In addition, knowledge of the impact of risk factors on vascular events, including stroke, is evolving as new evidence suggest that lower targets for risk factors such as hypertension, diabetes, and hyperlipidemia may be better.
In this article, we present an overview of the burden imposed by vascular risk factors, the impact of their modification on stroke risk and review standard recommendations for the modification of traditional stroke risk factors, as well as emerging evidence evaluating early treatment of risk factors where available and future lines of research.
Using the FSRP for stroke risk assessment The FSRP was developed using data from 36 years follow up in the Framingham cohort and has been validated in other cohorts [Voko et al. 2004; . The FSRP provides sex specific estimation of the probability of stroke using clinical information. By summing the points represented by individual risk factors, a table can be used to obtain the 10-year estimated risk of stroke (Table 1 ). An example of its use follows. A 65-year-old male presented to the stroke clinic, following an acute ischemic lacunar stroke that left him with mild residual left hemiparesis. He was diagnosed having hypertension (blood pressure 180/95 mm Hg), hyperlipidemia and diabetes during his recent hospitalization, and was smoking cigarettes daily. He received effective education and is now following recommendations, and compliant with treatments. He quit smoking, achieved satisfactory blood pressure and diabetes control, and is under target lipid levels. Using the FSRP, his baseline estimated ten year stroke risk was 19.5% (15 points); with effective treatment of the four modifiable risk factors the estimated risk is reduced to 8.4% (9 points). It is important to note that the FSRP is a useful tool in practice but should be used along with careful clinical judgment.
Treatment of risk factors
Stroke risk factors have been classified as traditional and novel, and modifiable and nonmodifiable. The nonmodifiable risk factors include age, sex, ethnicity/race, and family history. Stroke risk varies according to differences in these factors. Detailed review of their impact in stroke risk is available elsewhere [Wolf, 2004] .
Modifiable traditional risk factors include hypertension, diabetes, hyperlipidemia, atrial fibrillation, smoking, obesity, and carotid artery disease. Novel risk factors include hyperhomocysteinemia, hypercoagulable states, and select biomarkers. We will discuss further traditional risk factors, with exception of carotid artery disease reviewed in detail elsewhere [Sacco, 2001] .
Hypertension
Hypertension is the most prevalent modifiable risk factor for stroke with a prevalence of about 30% in the US [Rosamond et al. 2008] . The prevalence of hypertension increases with age, thus as the population ages, hypertension will become an even greater threat to public health, and is likely to increase as life expectancy increases. The Framingham Heart Study investigators reported the lifetime risk of hypertension to be ∼90% for men and women, who were nonhypertensive at age 55 or 65 years and survived to ages 80-85 years old [Vasan et al. 2002] . A meta-analysis of one million adults enrolled in 61 observational studies concluded that death from ischemic heart disease and stroke increases progressively and linearly with systolic blood pressure levels as low as 115 mm Hg and diastolic 75 mm Hg upward. This study also found that for every 20 mm Hg systolic or 10 mm Hg diastolic increase in blood pressure there is a doubling of mortality from both ischemic heart disease and stroke. The authors suggest a 10 mm Hg reduction in systolic or a 5 mm Hg reduction in diastolic blood pressure would result in a 40% lower risk of stroke death and a 30% lower risk of death from ischemic heart disease or other vascular death [Lewington et al. 2002] . Similarly, when Framingham Heart Study investigators looked at the difference in cardiovascular mortality between participants with blood pressure of 130-139/85-89 mm Hg and participants with blood pressure below 120/80 mm Hg, a greater than 2-fold increase in relative risk from cardiovascular disease was found [Vasan et al. 2001] . The United Kingdomtransient ischemic attack (TIA) trial looked specifically at blood pressure and risk of stroke in patients with known cerebrovascular disease and found a direct and continuous relationship between blood pressure and recurrent strokes. Their data demonstrated that a 5 mm Hg lower diastolic blood pressure was associated with nearly one third fewer strokes [Rodgers et al. 1996] .
Based on data such as these the 2003 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) redefined the classification of hypertension [Chobanian et al. 2003 ]. In the new classification, blood pressure <120/80 mm Hg was changed from 'optimal' to 'normal' and the new term 'prehypertension' was added signifying a systolic blood pressure of 120-139 mm Hg Review and/or diastolic blood pressure of 80-89 mm Hg. This reclassification of blood pressure was designed to encourage lifestyle changes at early stages of hypertension, and hopefully reduce the incidence of overt hypertension. The JNC-7 recommendation for treatment of pre-hypertension (in the absence of comorbidities, such as a history of diabetes or cardiovascular disease) is lifestyle change. Lifestyle change includes diet, mainly eating more fruits and vegetables and consuming less salt, in addition to weight loss, aerobic activity, and moderation of alcohol consumption. Pharmacological treatment is not recommended until systolic pressures exceed 140 mm Hg or diastolic exceeds 90 mm Hg [Chobanian et al. 2003 ]. However, given that the relationship between blood pressure and risk of coronary and cerebral vascular disease is continuous down to levels of a systolic blood pressure of 115 mm Hg and a diastolic blood pressure of 75 mm Hg, it is possible that earlier pharmacological treatment may be beneficial in combating the adverse effects of sustained prehypertension.
Review
Whereas, the necessity to treat hypertension to reduce the risk of cerebrovascular events is clear, there is less clarity regarding the best choice of antihypertensive medication. Though, not a trial designed to evaluate stroke risk reduction, the Heart Outcomes Prevention Evaluation (HOPE) Study demonstrated improved cardiovascular outcomes with the use of the angiotensinconverting enzyme inhibitor (ACEI) ramipril beyond its ability to lower blood pressure, which was very mild in this trial (the average reduction of systolic/diastolic blood pressure was 3/2 mm Hg) [Yusuf et al. 2000 ]. Subsequently, the Losartan Intervention for Endpoint reduction in hypertension (LIFE) Study compared the effects the angiotensin receptor blocker (ARB) losartan with the beta-blocker atenolol on the composite end-point of cardiovascular death, stroke, and myocardial infarction in patients with hypertension and left ventricular hypertrophy. When the endpoints were evaluated separately, a relative risk reduction of 25% was found in fatal and nonfatal stroke, favoring losartan over atenolol [Dahlof et al. 2002] . The perindopril protection against recurrent stroke study (PROGRESS) was the first trial to be done solely on patients with known cerebrovascular disease. Patients with a history of stroke or TIA were randomized to placebo, perindopril, or perindopril plus indapamide, a thiazide diuretic.
There were no blood pressure criteria for enrollment into the trial and the average blood pressure at entry was 147/86 mm Hg. The combination of indapamide and perindopril produced an average reduction in blood pressure of 12/5 mm Hg and was associated with a 43% reduction in relative risk of recurrent stroke compared with perindopril alone, which produced only a 5/3 mm Hg drop in blood pressure. This study raised the question of, whether or not it is the degree of reduction in blood pressure or the combination of an ACEI plus a thiazide that was responsible for the positive results [PROGRESS- Collaborative-Group 2001] . Lastly, in the Study on Cognition and Prognosis in the Elderly (SCOPE), elderly patients with isolated systolic hypertension were randomized to an ARB-based antihypertensive treatment with candesartan or nonARB-based treatment. Despite the similar degree of blood pressure lowering in the ARB arm (22/6 mm Hg) and in the nonARB arm (20/5 mm Hg) there was a 42% relative risk reduction in stroke in the ARB arm [Papademetriou et al. 2004 ]. These results suggest that ACEI and/or ARB, especially in combination with a thiazide diuretic, may be superior to other anti-hypertensive regimens in the secondary prevention of stroke.
Just as the choice of agent still is not certain, nor is the level of blood pressure reduction. Three randomized trials of more intensive vs. less intensive blood pressure control have shown that the more intensive control of blood pressure was superior in reducing the number of strokes, however, these were primarily in diabetic patients and only targeted diastolic blood pressures [Estacio et al. 1998; Hansson et al. 1998; UKPDS-Group-Investigators, 1998b] . One randomized trial showed that treatment of prehypertension was feasible and suppressed the onset of stage-1 hypertension in the treatment arm [Julius et al. 2006 ]. Clinical outcomes were not evaluated in this trial, so the effect of the medical treatment of prehypertension on reducing vascular events is not known.
Standard practice guidelines from recognized organizations such as the American Heart Association and American Stroke Association (AHA/ASA) have been written in regards to secondary prevention of stroke [Sacco et al. 2006 ]. Currently, antihypertensive treatment is recommended for all patients, who have had a TIA or a stroke, and is even to be considered in patients, who are normotensive. The ideal goal blood pressure is still uncertain and should be individualized, but benefit has been seen with an average blood pressure reduction of ∼10/5 mm Hg [Sacco et al. 2006 ]. The agent of choice depends on individual patient characteristics, but ACEI and ARB in addition to a diuretic seem to be favorable in patients with stroke, based on data from the aforementioned trials.
Future trials focusing on the outcomes of treating blood pressure at earlier stages are needed. Ideally, such a trial would compare the effects of several anti-hypertensive agents to also establish whether or not one class of drugs should be chosen over another. Currently there are two on-going trials that will hopefully partially answer these questions. The Secondary Prevention of Small Subcortical Strokes (SPS3) trial, which is comparing different antiplatelet therapies in stroke prevention in patients with lacunar strokes, is also assessing the effects of different blood pressure targets, i.e., systolic blood pressure <150 mm Hg vs. a target blood pressure <130 mm Hg. The On Going Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) is comparing the ACEI ramipril vs. the ARB telmisartan vs. a combination of both in high-risk patients for reductions in major vascular events.
Finally, although several treatment options exist, effective use of these treatments is limited by lack of awareness of hypertension in patients; prior studies have shown that only about 60% of hypertensive individuals were aware of having hypertension. In addition, once recognized effective treatment is achieved only in a minority. Approximately one third of hypertensive individuals are controlled to target blood pressure, according to prior studies [Hajjar et al. 2006] . Therefore, especial attention should be paid to patient education and follow up to ensure effective blood pressure control.
Diabetes
Diabetes affects 9.6% of Americans over the age of 20 years and 21% of Americans over the age of 60 years [Rosamond et al. 2008 ].
According to the NIH National Statistics on Diabetes, the estimated number of Americans with diabetes is 20.8 million with an additional 41 million with prediabetes [National-Diabetes- Statistics-NIDDK 2005] . With the rise in the obesity epidemic and the rising age of the population this number will undoubtedly increase in the future. The relative risk of stroke in a person with diabetes ranges from 1.8 to 6.0 and diabetics tend to have strokes at a younger age [Rosamond et al. 2008 ]. Pre-diabetes is a risk factor for the development of diabetes mellitus and, in patients with a history of TIA or stroke, impaired glucose tolerance doubles the risk of stroke [Vermeer et al. 2006 ].
In 2003 While, diabetes is a known risk factor for vascular disease and stroke, more data support the idea that the effects of abnormal blood glucose can have adverse health consequences, even before frank diabetes develops [Vermeer et al. 2006 ]. The association of IGT and insulin resistance with an increase risk of stroke has been demonstrated in several studies [Kaarisalo et al. 2006; Vermeer et al. 2006; Kernan et al. 2002; Pyorala et al. 2000 ]. Early intervention, including lifestyle change [Lindstrom et al. 2006 ] and pharmacological treatment, [Knowler et al. 2002] has been shown to reduce or delay the diagnosis of diabetes. This could have significant impact on the development of cerebrovascular disease, as well as outcome from an acute stroke. Hyperglycemia in the setting of an acute stroke is known to extend the ischemic penumbra and has an adverse effect on neurologic outcome [Parsons et al. 2002] . Diabetes increases poststroke mortality and adversely affects post-stroke outcomes as compared with stroke patients without diabetes [Bruno et al. 2002] . However, while many trials have proven early recognition and treatment of IGT may prevent diabetes, the Review effect of early treatment on cardiovascular disease and stroke remains unknown.
The choice of agent in the treatment of prediabetes may also be important, as some agents may not be safe. In the DREAM trial the thiazolidinedione rosiglitazone reduced the frequency of diabetes in individuals with prediabetes, however the study did not have sufficient power to detect differences in cardiovascular outcomes [Gerstein et al. 2006 ]. A subsequent meta-analysis of 42 trials comparing rosiglitazone to placebo or other antidiabetic agent revealed a borderline statistically significant increase in the risk of death form cardiovascular causes (OR 1.43 for myocardial infarction and 1.64 for death from cardiovascular causes in the rosiglitazone group) [Nissen and Wolski 2007] . In contrast, the other currently available thiazolidinedione, pioglitazone, was not shown to have the same cardiovascular risk in patients with diabetes in the Proactive Study [Dormandy et al. 2005 ].
The UK Prospective Diabetes Study showed that glycemic control has been shown to reduce the microvascular events of nephropathy, retinopathy, and peripheral neuropathy, but its effects on macrovascular disease, such as stroke and myocardial infarction, are less clear [UKPDS-Group-Investigators, 1998a ]. However, if attention is focused on more rigorous control of blood pressure with a goal of <130/80 mm Hg and lipids, with an LDL goal of <100 mg/dl, and treatment with anti-platelet agents, the macrovascular complications of diabetes can be reduced [Arauz-Pacheco et al. 2002; Haffner, 1998; Colwell, 1997] . For blood pressure reduction, ACEI and ARBs are preferred in diabetics as they have been shown to reduce microalbuminuria [HOPE-Study-Investigators, 2000 ]. This may be significant for the reduction in cerebrovascular disease, as new data linking kidney disease and cerebrovascular disease are emerging [Ikram et al.2008] .
For now, clear evidence-based data support that prediabetes is a significant risk factor for the development of diabetes and increases one's risk for cardiovascular and cerebrovascular disease. It has also been shown that early modifications in lifestyle and the initiation of medications can prevent the development of diabetes. Once a person has diabetes, aggressive blood pressure, and lipid management, along with anti-platelet therapy is beneficial in reducing the macrovascular complications of diabetes. The effects of early treatment of prediabetes in reducing macrovascular events, including stroke, remains to be determined.
As in the case of hypertension, patient recognition of diabetes, and effective treatment is limited in clinical practice. Therefore, emphasis should be placed on patient education and follow up to achieve glucose control.
Recently, the presumption that more aggressive blood sugar control is better has been brought into question. The Action to Control Cardiovascular Risk in Diabetes Mellitus (ACCORD) trial was designed to evaluate aggressive management of glycemia, lipidemia, and blood pressure in patients with diabetes, who are considered high-risk for major cardiovascular events.
In addition to assessing the efficacy of a target HbA1c of <6% vs. 7-7.9% and adding a fibrate to a statin for lipid control, the target SBP of <120 mm Hg vs. <140 mm Hg is being examined. The aggressive glucose control arm (target HbA1c <6%) of this trial has been stopped 18 months early due to an increase in death in the intensive treatment arm (1.4 deaths per 100 patients per year vs. 1.1 per 100 patients per year in the standard treatment program). However, subjects in the intensive arm (HbA1c <6%) will continue to be followed for aggressive blood pressure and lipid control, but will now aim for a less-intensive glycemic target [Accord-Study-Group, 2008] .
Research on pre-diabetes is ongoing in the Insulin Resistance Intervention After Stroke Trial (IRIS). This trial is looking at the effect of pioglitazone on secondary stroke prevention in patients with insulin resistance, who have had a TIA or a stroke. This trial hopes to complete data collection on over 3000 patients by June of 2009. Future studies designed to address the appropriate timing of preventative treatment, the appropriate therapy (lifestyle modification vs. medications) and the safe targets for glycemic control in the prevention of stroke and cardiovascular disease are needed.
Atrial fibrillation
Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the relative risk of stroke 2.6 to 4.5 fold depending on the age group . Framingham Investigators have estimated that the lifetime risk for development of AF is one in four for men and women at age 40 years [Lloyd-Jones et al. 2004 ]. AF increases with age, is the underlying mechanism of ∼15% of all strokes, and is associated with strokes that carry higher mortality and disability, compared with nonAF related ischemic strokes [Wattigney et al. 2003; Lin et al. 1996; Sandercock et al. 1992] .
Several prospective randomized trials have shown the benefit of anticoagulation with warfarin for stroke prevention in patients with AF (AFASAK [Petersen et al. 1989 ], BAATAF, SPAF III [SPAF-III-Trial-Investigators 1996], EAFT (European-Atrial-Fibrillation-Trial-Investigators, 1993). In patients treated with adjusteddose warfarin, the relative risk reduction of stroke is 68% (95% CI, 50 to 79) and the absolute annual risk is reduced from 4.5% to 1.4% [Sacco et al. 2006; Atrial-Fibrillation-Investigators, 1994 ].
Since anticoagulation with warfarin carries an ∼1% per year risk of serious and fatal hemorrhage, careful assessment of the risks and benefits should be considered. Risk assessment models have been developed for estimation of stroke risk in patients with AF, including FSRP and CHADS2 score system, which are useful when balancing the risks and benefits of anticoagulation. In patients without other risk factors (CHADS2 score <1), patients with AF have an estimated stroke risk of 1% per year, which lessens the potential benefit of anticoagulation with warfarin compared with its potential risk.
Current guidelines recommend anticoagulation with adjusted-dose warfarin (target INR, 2.5; range, 2.0 to 3.0) in patients with persistent or paroxysmal AF at high risk for stroke (age >75, prior ischemic stroke,TIA, or systemic embolism, moderate or severe left ventricular function impairment or congestive heart failure, history of hypertension or diabetes). On the other hand, for patients with nonvalvular lone AF (without other risk factors) or those with contraindications for warfarin therapy, aspirin is recommended [Sacco et al. 2006 ].
Despite its proven benefit, anticoagulation for stroke prevention is underutilized in patients with AF. Prior studies suggest that only 20 to 58% of patients eligible for anticoagulation actually receive it Go et al. 2003] . A common reason cited by physicians to deny patients treatment with warfarin is a perceived fall risk, often attributed to age. However, this should rarely be used as a justification to withhold warfarin from moderate risk patients with atrial fibrillation [Man- Son-Hing and Laupacis, 2003 ]. According to one decision analytic model, a person with AF with an average risk of stroke (5% per year) must fall approximately 300 times a year to make the risk of a subdural hematoma outweigh the benefits of stroke reduction with warfarin [Man- Son-Hing et al. 1999 ]. In addition, in clinical practice, clinicians also observe development of ecchymosis with trivial trauma, which may limit acceptance of this treatment by patients. Nevertheless, at present coumadin is the best choice for most patients despite its risks.
One of the most important aspects of treatment with warfarin is close monitoring of anticoagulation. If the INR is subtherapeutic (below 2.0) the risk of ischemic stroke increases (double at an INR of 1.7, triple at an INR of 1.5) [Hylek et al. 1996] , and if the INR is supratherapeutic (above 3.0) the risk of fatal intracerebral hemorrhage increases significantly [Levine et al. 2004] . While maintenance of the INR in this therapeutic range may be challenging, development of anticoagulation clinics has been shown to improve the safety of warfarin use and increase the likelihood of maintaining a therapeutic INR.
Although warfarin remains a 'gold standard' for stroke prevention in AF patients, there is a need for new anticoagulant agents as effective, but with less hemorrhagic complications and without the rigorous monitoring schedule required.
The SPORTIF III and V randomized trials showed that ximelagatran (direct thrombin inhibitor) is as effective as warfarin, with few hemorrhagic complications, but its use was associated with marked liver dysfunction, and did not meet safety requirements for approval in the US [Olsson, 2003] . Several other direct factor Xa inhibitors are in different stages of clinical development, including rivaroxaban, LY517717, YM150, DU-176b, apixaban, and betrixaban [Turpie, 2008] . Rivaroxaban was shown to be more effective when compared to enoxaparin in postoperative prevention of venous thromboembolic events, [Fisher et al. 2007] and is undergoing evaluation as a treatment for prevention of stroke in AF. Similarly, a reversible Review thrombin inhibitor (dabigatran etexilate) is currently being studied in a phase III trial evaluating its benefit in prevention of stroke or systemic embolism in patients with AF [Mungall, 2002] .
Lastly, research evaluating the genetic basis of AF as well as genetic considerations for the treatment of AF is beginning to influence treatment decisions for stroke prevention. For instance, the FDA recently approved two new genetic tests (CYP2C9 and VKORC1), [Rieder et al. 2005; Linder et al. 2002] designed to aid in more precise initial dosing of warfarin. Although, further randomized trials are required to evaluate concomitant influential factors, an economic analysis found that integration of genetic tests into warfarin therapy significantly improves health outcomes and reduces healthcare costs. Guidelines for pharmacogenomics-based warfarin dosing are under development [Hampton, 2006; Sconce et al. 2005] .
Hyperlipidemia
Several large randomized trials of statins have demonstrated reduction of stroke risk associated with lowering lipid levels. However, observational prospective studies have not found a consistent relation between cholesterol levels and incidence of stroke [Shahar et al. 2003 ]. The beneficial effects of statins on stroke risk reduction may be mediated by additional mechanisms of action such as improvement of endothelial function, antioxidant properties, inhibition of inflammatory responses, immunomodulatory actions, and stabilization of atherosclerotic lesions [Endres, 2005] .
Although, the agent used, and the dose has varied across studies, the results have been consistent, showing stroke relative risk reduction ranging approximately from 10 to 50% [Colhoun et al. 2004; Collins et al. 2004; Sever et al. 2003; Athyros et al. 2002; UKPDS-Group-Investigators, 1998a] . Most studies included patients with concomitant coronary heart disease; thus it had been less clear if the benefit in stroke risk reduction was secondary to reduction of myocardial infarction and cardiac death. The first trial evaluating directly the impact of cholesterol lowering therapy in stroke risk in patients without coronary heart disease was the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study (SPARCL). The trial compared 2365 patients with recent TIA or stroke (within 6 months of enrollment) that had no known coronary heart disease assigned to Atorvastatin 80 mg daily to 2366 patients assigned to a placebo group. This study found an absolute risk reduction in stroke rates of 2.2% (adjusted HR 0.84; 95% CI 0.71 to 0.99). This was associated with a reduction of LDL cholesterol levels of 53% (p < 0.001). Although, there were more hemorrhagic strokes in the atorvastatin group (55 vs. 33 in the placebo group), the incidence of fatal hemorrhagic stroke was not significantly different between the groups [Amarenco et al. 2006; Amarenco, 2005] .
Of note, there is evidence suggesting that use of statins at the time of an ischemic stroke may have beneficial effects. The Northern Manhattan Study found that the 90-day mortality rate was lower in patients who were taking a statin compared to those not taking it at the time of stroke (1.8% vs. 10.6%, p = 0.03) [Elkind et al. 2005] . Other studies support the finding of reduced degree of stroke severity and better outcomes if lipid-lowering agents were used prior to the vascular event ]. In addition, withdrawal of statin treatment at the time of an acute ischemic stroke has been related to poorer neurological outcome at 90 days [Blanco et al. 2007 ]. Interestingly, one small study also showed that patients using statins prior to treatment with thrombolytics had better neurological outcome at 3 months [Alvarez-Sabin et al. 2007] .
At present, practice guidelines recommend use of statins for secondary prevention of stroke. The target LDL level varies depending on the patient's estimated risk, <100 mg/dL for those with symptomatic atherosclerotic disease, and <70 mg/dL for those at very high risk.
Very high risk is considered when there is established cardiovascular disease and one of the following: multiple major risk factors, poorly controlled risk factors (smoking), the metabolic syndrome (mainly triglycerides >200 mg/dL with low high-density lipoprotein (HDL) cholesterol <40 mg/dL), and acute coronary syndromes [Sacco et al. 2006 ].
Additionally, although traditionally more attention is given to LDL levels, attention should also be paid to HDL levels. Prior studies in large cohorts have shown an inverse association between serum HDL cholesterol and stroke [Curb et al. 2004 ]. HDL cholesterol is involved in atherosclerosis and its higher levels have been related to anti-atherosclerotic and antiinflammatory properties in animal and human studies [Tall, 1990] . A prior study found that high serum HDL levels were associated with reduced odds of having a large-vessel stroke (OR 0.8, 95% CI 0.6 -1) [Tirschwell et al. 2004 ]. Observations in young stroke patients demonstrated that low HDL level is associated with an increased risk of stroke [Albucher et al. 2000 ]. Treatment considerations include the addition of niacin or fibrates in patients with HDL <40 mg/dL [Sacco et al. 2006 ].
Smoking
In the US, nearly 25% of adults are affected by cigarette smoking [CDC 2004] .
Smoking is an independent stroke risk factor, increasing the risk of stroke by about 50% [Shinton and Beevers, 1989 ]. The risk increases proportionally with the number of cigarettes smoked per day and passive smoking also increases the risk of ischemic stroke.
Smoking cessation is an effective measure to reduce stroke risk. Several options are available for effective smoking cessation. Treatment involves counseling, and pharmacologic interventions such as nicotine replacement, antidepressant agents such nortriptyline or bupropion, and more recently varenicicline.
The value of medical counseling should not be overlooked as it increases by about 70% the success of smoking cessation (OR 1.69, 95% CI 1.45-1.98) ]. Nicotine replacement also has been found to increase the likelihood of smoking cessation by about 70% (OR 1.71, 95% CI 1.60-1.83), regardless of the product used Silagy et al. 2000 ]. In a prior study, the antidepressant nortriptyline was effective increasing the rate of smoking cessation at six months with an absolute difference of 11% compared to placebo (95% CI -18% to -4%) [Prochazka et al. 1998 ]. Bupropion, an atypical antidepressant, also has been found to be effective attaining smoking cessation. In a study comparing bupropion alone or in combination with nicotine replacement vs. placebo, treatment with bupropion resulted in higher cessation rates at 12 months compared to placebo (OR 2.3, 95% CI 1.4 to 3.9). There was a higher benefit with the combined use of bupropion and a nicotine patch (OR 3.0, 95% CI 1.8-4.9) Jorenby et al. 1999] .
More recently, a randomized trial evaluated the partial nicotinic acetylcholine receptor agonist varenicicline [Gonzales et al. 2006 ]. The study included 1025 partici-pants randomized to varenicicline, bupropion, or placebo for 12 weeks. This study showed a significant increase in smoking cessation rates at 52 weeks for varenicicline compared to placebo (OR 3.09, 95% CI 1.95-4.91) and to bupropion (OR 1.46, 95%CI 0.99-2.17). The most common side effects were nausea (28%) and insomnia (21%). Other studies are showing similar results, and the FDA has approved varenicicline for smoking cessation, offering an alternative option for patients.
Smoking cessation is recommended for all patients with stroke or TIA, and should be encouraged during all encounters with patients. Education at the individual level along with stricter policies for global regulation for tobacco control are likely to increase the efficacy of smoking cessation strategies for the public.
Obesity
Obesity has been related to increased risk of cardiovascular events, disability and mortality [Flegal et al. 2005] . The risk of ischemic stroke also increases with obesity, being about three times for obese individuals in prior studies (OR 3.0, 95% CI 2.1-4.2) [Suk et al. 2003 ]. Approximately a 30% prevalence of obesity has been estimated in the US [Flegal et al. 2002] . Obese individuals also have more prevalent associated risk factors such as hypertension, diabetes, and hyperlipidemia. Prior studies suggest that the distribution of fat may be relevant, with abdominal fat being more associated to the risk of stroke, particularly in men.
Current guidelines recommend considering weight reduction for stroke prevention, targeting body mass index 18.5 to 24.9 kg/m 2 and waist circumference lower than 35 inches for women and 40 inches for men [Sacco et al. 2006 ]. The main impact of weight loss in the risk of stroke may be mediated by improved control of other risk factors. Prior studies have shown that in obese persons, weight loss results in better control of hypertension, blood glucose, and lipid levels.
Although, not directly indicated for obesity, current guidelines for stroke prevention include Review Table 2 . Effects of treatment of risk factors in primary prevention of stroke.
Risk factor Evidence Risk reduction Management/Comments
Hypertension Chobanian et al. 2003] Class I A 35-44% Screening every 2 years. Individualized management and choice of agent. Life style modification. Goal BP <140/90 mm Hg for usual care and <130/80 for compelling indications. † Pre-Hypertension [Chobanian et al. 2003] No data -Life style modification
Diabetes
Glycemic control [Ryden et al. 2007] Data lacking to support effect on stroke reduction -Reduction of microvascular complications, but not macrovascular. Emphasis on aggressive management of other risk factors in patients with diabetes. Hypertension control Chobanian et al. 2003; UKPDS-Group-Investigators, 1998b] Class I A 20-44% Goal BP < 130/80 mm Hg. ACEI/ARB are preferred agents in patients with diabetes and microalbuminuria.
Hyperlipidemia dietary recommendations to increase the content of vegetables and fruits, as well as a diet with low fat dairy products with low content of saturated fat, in addition to reduced intake of sodium and increased intake of potassium. A diet as such is beneficial to reduce blood pressure and may therefore be beneficial for reducing stroke risk ].
Ensuring practice of recommendations
Although enough evidence is available for effective modification of stroke risk factors, in practice treatments are underutilized and lack of patient awareness of risk factors remains an obstacle. Recently, Bodenheimer presented a model for practicing evidence based medicine including five steps, from discovery of evidence [Sacco et al. 2006] Not directly studied -Diet and physical activity has been linked to a reduced stroke risk.
Abdominal obesity more strongly associated with stroke risk. Weight loss improves blood pressure. Consider weight reduction (diet, physical activity) for all. Goal BMI 18.5 to 24.9 kg/m 2 and waist circumference of 24 inches for men, 32 for women.
Evidence class and level defined in Table 2 . BP = Blood Pressure; BMI = body mass index.
by research efforts, continuing with learning of the evidence by clinicians and using it in daily practice with all patients, followed by ensuring understanding by patients and finally assisting patients to incorporate evidence in their lives [Bodenheimer, 2007] . In practice, patient encounters are limited by time constraints, which interferes with application of these principles. A multidisciplinary effort aids to make this process feasible and effective.
Recent efforts by the AHA/ASA have been made to bridge the gap between theory and practice in stroke care, resulting in standardization of stroke centers and development of quality control programs such as 'Get With the Guidelines'. This program provides resources for centers and clinicians to initiate risk factor modification for patients while they are in the hospital. Another program, the Preventing Recurrence Of Thromboembolic Events through Coordinated Treatment (PROTECT) program, also provides measures to initiate stroke prevention at the time of hospital admission. This model, proposes follow up 1-3 weeks after hospitalization by means of a phone call, to assess side effects of medications and compliance with medications and life style changes, a 6-week post hospitalization laboratory monitoring to ensure that targets for lipid levels are achieved and monitor liver function parameters, and 3 month and 1 year visits for comprehensive evaluation including compliance with medications, life style changes, assessment of vascular outcomes and laboratory monitoring of lipid targets and liver parameters [Ovbiagele and Saver, 2006 ]. Programs like these will likely improve patient care, however in clinical practice care is individualized using careful clinical judgment, and should also consider the patient's cultural background.
Conclusion
A summary of the treatment of modifiable risk factors for primary and secondary stroke prevention is presented in Tables 2 and 3. Modification of risk factors is the main resource for effective prevention of stroke. Many therapeutic options are available at present, and continued research efforts are expanding the available options. However, clinicians and patients face a challenge to put in practice all the evidence available. A multidisciplinary approach with organized continued education will likely improve the efficacy of these measures.
In the near future, studies embarking on the evaluation of the genetic determinants of cerebrovascular risk factors and outcomes, will increase our understanding of cerebrovascular disease and will likely result in new therapies, with individualized programs for stroke prevention.
